Menu
1 min read · estimated
APPROVED USE
What FDA approved
Children aged 2 years and older with FDA test-confirmed RET-altered tumors: advanced or metastatic RET-mutant medullary thyroid cancer needing systemic therapy; advanced or metastatic RET fusion-positive thyroid cancer needing systemic therapy and refractory to radioactive iodine when appropriate; or locally advanced or metastatic RET fusion-positive solid tumors after systemic treatment progression or without satisfactory alternatives.
LAMPGEN ANALYSIS
Why it matters
The pediatric extension brought RET-targeted treatment to younger children across several rare populations.
What research teams should watch
Use the disease-specific RET test and eligibility criteria, and coordinate age-appropriate drug administration and pediatric follow-up.
PRIMARY RECORDS